Product Images Memantine Hydrochloride

NDC 55154-2667-0 is a prescription drug used in the treatment of Alzheimer's disease called Memantine HCI which comes in the form of tablets with each tablet containing 10 mg of memantine hydrochloride. The recommended storage temperature is 25°C (77°F), and excursions are allowed between 15°C to 30°C (39°F to 86°F). Children should not have access to this medication because it is not child-resistant. It has been licensed from Merz Pharma GmbH & Co. KGaA and is produced in Ireland. Actaus Pharma, Inc. in Parsippany, NJ, and Cardinal Health in Dublin, OH, distributed the medication. Detailed information on dosage, administration, and other warnings is included in the package insert.*

This is a medication package containing 10 tablets of Memantine HCI, each tablet containing 5 mg of memantine hydrochloride. The recommended dosage and administration instructions are available in the product insert. The storage temperature should be at 25° C (77 F), with excursions permitted to 15°C-30° C (59" F to 85" F). This package is intended for institutional use only and is not child-resistant. It is distributed by Actaus Pharma, Inc, Parsippany, NJ, USA, and licensed from Merz Pharia GmbH & Co. KGaA.*

This is a graph illustrating the improvement in ADCS-ADL score for patients who completed a 28-week treatment. The x-axis shows the weeks of treatment, while the y-axis displays the mean (± SEM) change from baseline. The title of the graph suggests that there was improvement in ADCS-ADL scores over the course of the 28 weeks.*

The text appears to be a graph caption showing the change from baseline in ADCS-ADL scores of patients completing 28 weeks of double-blind treatment. The graph is not available, only the caption.*

The figure shows the time course of the change from baseline in SIB score for patients who completed 28 weeks of treatment. No further information is available.*

The text describes a graph labeled "Figure 4" that shows the cumulative percentage of patients who completed 28 weeks of double-blind treatment. The graph measures the specified changes from baseline in SIB scores. However, there is not enough information to provide a more detailed description.*

The text shows a graph labeled as "Figure 5" displaying patients' change from the baseline in ADCS-ADL Score at 24 weeks of treatment. No other information is available.*

The text describes a graph or figure showing the time course of patients who completed 24 weeks of treatment and the change in their SIB score from baseline. The units of measurement for the SIB score are not provided and the text is too short to provide further context.*

The text describes a figure showing the cumulative percentage of patients who completed 24 weeks of double-blind treatment with specified changes from baseline in SIB scores. However, there is some illegible text at the beginning that cannot be interpreted.*